Manulife (Manufacturers Life Insurance)
OVID icon

Manulife (Manufacturers Life Insurance)’s Ovid Therapeutics OVID Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,980
Closed -$79.2K – 3028
2024
Q1 		$79.2K Buy
25,980
+1,130
+5% +$3.78K ﹤0.01% 2830
2023
Q4 		$80K Hold
24,850
– – ﹤0.01% 2869
2023
Q3 		$95.4K Hold
24,850
– – ﹤0.01% 2826
2023
Q2 		$81.5K Buy
+24,850
New +$84.4K ﹤0.01% 2912
2021
Q2 		– Sell
-31,332
Closed -$126K – 3268
2021
Q1 		$126K Buy
+31,332
New +$104K ﹤0.01% 3019
2020
Q4 		– Sell
-26,446
Closed -$152K – 3020
2020
Q3 		$152K Hold
26,446
– – ﹤0.01% 2673
2020
Q2 		$203K Buy
+26,446
New +$124K ﹤0.01% 2493
2018
Q3 		– Sell
-1,011
Closed -$8K – 3588
2018
Q2 		$8K Hold
1,011
– – ﹤0.01% 3955
2018
Q1 		$7K Sell
1,011
-813
-45% -$6.58K ﹤0.01% 4031
2017
Q4 		$18K Buy
1,824
+891
+95% +$8.18K ﹤0.01% 3826
2017
Q3 		$8K Buy
+933
New +$7.77K ﹤0.01% 3908

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s OVID Position: Q2 2024 in Review

Manulife (Manufacturers Life Insurance) sold out of Ovid Therapeutics (OVID) in Q2 2024, closing a stake of 25,980 shares — an estimated $79.2K sold.

Manulife (Manufacturers Life Insurance) first reported a position in OVID in Q3 2017 and held it in 11 quarters. The position peaked at $203K in Q2 2020. 74 funds tracked by Wall St. Rank hold OVID as of Q2 2024.

  • Manulife (Manufacturers Life Insurance) reported no remaining Ovid Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 25,980 Ovid Therapeutics shares in Q2 2024, an estimated $79.2K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Ovid Therapeutics in Q3 2017 and held it in 11 quarters.
  • Manulife (Manufacturers Life Insurance)'s Ovid Therapeutics position peaked at $203K in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2024.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2024, filed 14 Aug 2024.